How Molecular Markers Affect MPN Treatment | Advances in Research

preview_player
Показать описание
Are there new molecular markers being discovered that could affect myeloproliferative neoplasm (MPN) care? Dr. Lucia Masarova explains common MPN driver mutations and what researchers are learning about recently discovered molecular markers, such as ASXL1.

  1. Patient Empowerment Network
Рекомендации по теме
How Molecular Markers 0:02:57

How Molecular Markers Affect MPN Treatment | Advances in Research

How Does the 0:03:16

How Does the Presence of Molecular Markers Affect AML Care?

MPN Treatment: What 0:03:14

MPN Treatment: What Is the Role of Biomarkers?

Expert Perspectives: MPN 0:27:35

Expert Perspectives: MPN and MDS

MPN Essential Testing 0:04:23

MPN Essential Testing | How Results Impact Care & Treatment Options

Myeloproliferative Neoplasms in 0:26:23

Myeloproliferative Neoplasms in 2014: Morphology, Molecular Genetics, and Test Utilization

CML molecular monitoring: 0:21:14

CML molecular monitoring: Practical advice

Use of Molecular 0:22:18

Use of Molecular Genetic Testing in MDS and MPN

Finding Hope in 0:13:05

Finding Hope in Treatment: New Developments in MPN Research 2023

Biomarkers and Molecular 0:29:51

Biomarkers and Molecular Abnormalities: What Do Patients Need to Know? Alison Moliterno, MD

Interplay of Somatic 0:27:39

Interplay of Somatic and Germline Variants in MPN

Effects of tamoxifen 0:09:24

Effects of tamoxifen on the mutant allele burden in MPNs

MPN updates with 0:46:59

MPN updates with Q and A with Dr Humphrey Pullon

Combination Therapy with 0:24:52

Combination Therapy with JAK2 inhibitors in MPN

Imetelstat shows promise 0:04:39

Imetelstat shows promise in advanced myelofibrosis

Understanding Myelofibrosis: Molecular 1:20:00

Understanding Myelofibrosis: Molecular Biology, JAK Inhibitors, and Emerging Therapeutics

Understanding the Molecular 0:03:25

Understanding the Molecular Pathophysiology of Polycythemia Vera

Ronald Hoffman, MD 0:35:19

Ronald Hoffman, MD - Drivers of Progression of MPNs

Influence of Mutational 0:22:27

Influence of Mutational Status on Timing, Outcome, and Post-transplant Management of Myelofibrosis

Conversation with MPN 1:52:43

Conversation with MPN Specialists: Focus on Myelofibrosis

MPN Transformation to 0:20:12

MPN Transformation to MDS and AML: Risk factors, therapy and outcomes

SCOG Virtual Lecture 0:42:57

SCOG Virtual Lecture Series - Mark Hartmann (DKFZ, Heidelberg)

“Nobody told me 0:59:54

“Nobody told me I had cancer”.MyeloproliferativeNeoplasms (MPN)explained - Dr Alwyn D’Souza

What is new 0:30:30

What is new in thrombosis in MPN